Business Context and Reporting Period
Company: GAXOS.AI INC. (Ticker: GXAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: GAXOS.AI is a technology company developing AI applications across defense, health, entertainment, and productivity sectors. Key initiatives include Gaxos Labs (AI for game developers), Gaxos Health (AI-powered wellness), and RNK Health (non-clinical administrative services for telehealth). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,809,367 | $23,732 |
| Net Loss | $(2,474,246) | $(1,232,062) |
| Net Loss Attributable to Common Shareholders | $(2,172,525) | $(1,191,800) |
| Loss Per Share (Basic & Diluted) | $(0.25) | $(0.17) |
| Cash and Cash Equivalents | $1,513,550 | $2,571,340 |
| Short-Term Investments | $10,195,791 | $11,345,187 |
| Working Capital | $11,587,582 | $11,919,230 |
| Total Liabilities | $569,308 | $680,589 |
Note: The filing does not provide a specific "Cost of Revenue" line item; operating expenses are reported separately. Gross margin is not explicitly stated.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by approximately 7,527% year-over-year, driven primarily by RNK Health administrative services ($1.25M vs. $22.5K) and subscription services from Gaxos Labs ($563K vs. $51).
- Expense Growth: Operating expenses rose 207.8% to $4.36M. This was largely due to a 1,169.9% increase in advertising and marketing expenses ($2.77M vs. $218K) to support RNK Health and Gaxos Labs, and a 102% increase in R&D expenses.
- Net Loss Expansion: Net loss doubled to $2.47M, reflecting the aggressive investment in marketing and development despite revenue growth.
- Capital Raise: The company issued 3,096,481 shares of common stock via an At-The-Market (ATM) offering, generating net proceeds of approximately $5.32M.
- Strategic Investment: The company acquired a 19.99% membership interest in America First Defense.AI LLC for $2.9M, recorded as a long-term investment.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($1.5M) and short-term investments ($10.2M) are sufficient to meet operating needs for the next 12 months. The company expects to continue generating operating losses in the foreseeable future.
- Product Pipeline: Recent launches include UnGPT.ai (text enhancement), Art-Gen.AI (image/video creation), and Bible Pray AI (spiritual growth). Gaxos Labs continues to expand its generative AI services for game developers.
- Key Risks:
- Regulatory Uncertainty: RNK Health's revenue depends on a third-party Medical Partner. Changes in state laws regarding telehealth or legal challenges to the partner's business model could materially impact revenue.
- Capital Requirements: Future success depends on obtaining additional financing. The company has an ATM agreement with H.C. Wainwright to raise up to $6.665M (increased from $5.6M).
- Market Competition: Risks related to attracting/retaining users, advertisers, and competing with new market entrants in the AI space.
- Unusual Items: The company recorded a $400,000 discretionary bonus for the CEO. Unrealized losses on short-term investments and equity securities impacted comprehensive loss.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the RNK Health partnership and the regulatory environment for telehealth services in key states.
- Burn Rate vs. Cash Runway: Confirm the $12M+ liquidity position against the current quarterly cash burn of ~$2.5M to validate the 12-month runway claim.
- Marketing Efficiency: Assess the return on investment for the $2.77M marketing spend, specifically regarding user acquisition costs for Gaxos Labs and RNK Health.
- Investment Valuation: Review the terms and valuation methodology for the $2.9M investment in America First Defense.AI LLC.
- Dilution Impact: Monitor the pace of share issuance under the ATM agreement and its impact on earnings per share.